U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228364) titled 'Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease' on Oct. 23.
Brief Summary: A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Study Start Date: Dec. 02
Study Type: INTERVENTIONAL
Condition:
Autosomal Dominant Polycystic Kidney Disease
Intervention:
DRUG: AZD1613 - Part A
Part A - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.
DRUG: Placebo - Par...